Transcenta

Merry Christmas! 🎅 ❄️ Wishing you a holiday filled with laughter and joy, making memories you’ll cherish for years to come. 💗 As we welcome 2025, may the new year bring you prosperity, good health, and countless opportunities for growth and happiness. 💕

Transcenta announces late-breaking presentation of preclinical study results of novel humanized LIV-1 antibody based ADCs at 2024 San Antonio Breast Cancer Symposium (SABCS). The ADCs (ADC-1 and ADC-2) were engineered using Transcenta's proprietary antibody with site-specifical conjugation of Topoisomerase I Inhibitor payloads and these ADCs demonstrated significantly higher tumor regression activities than MMAE based ADCs in triple-negative breast cancer (TNBC) tumor models. Read more: https://lnkd.in/gd_8rWkh

Thanksgiving is the time when we reflect on what matters the most. At Transcenta, we are thankful for our amazing team members and partners, who enable us to employ cutting-edge technology and innovate to help patients with differentiated and affordable biologics. We are honored to work, learn, and grow together. Happy Thanksgiving to you and your loved ones! 🦃🍁

With a five-year survival rate in the single digits, pancreatic cancer is one of the world’s deadliest cancers. One of the reasons for this low survival rate is a general lack of knowledge about the pancreas. Say “Hello Pancreas” and learn to recognize the signs and symptoms of pancreatic cancer: unexpected weight loss, new-onset diabetes, yellow skin or eyes, and more. Early diagnosis is vital and may increase the chances of survival. Take action to learn more about the pancreas and raise awareness about pancreatic cancer: https://lnkd.in/dxAi_fz2

Today is World Osteoporosis Day🦴 Worldwide, one in three women and one in five men aged 50 years and over will suffer an osteoporotic fracture. Osteoporosis causes bones to become weak and fragile, so that they break easily - even as a result of a minor fall, a bump, a sneeze, or a sudden movement. Fractures caused by osteoporosis can be life-threatening and a major cause of pain and long-term disability. To become aware of any potential risk factors, you can take the IOF Osteoporosis Risk Check: https://lnkd.in/gegpt-w6 Let's spread awareness this World Osteoporosis Day! 

Transcenta sincerely invites you to our 2024 ESMO Business Update Call. Please scan the QR code or register through the below link to join the call. DATE: Sep 27, 2024 Friday TIME: 10:00am HKT LANGUAGE: English https://lnkd.in/gZ2sR7Ru

Transcenta announces the updated results from the cohort-G data for Osemitamab (TST001) plus Nivolumab and CAPOX as the first-line treatment for the patients with advanced G/GEJ cancer (TranStar102). The updated data continues to show encouraging efficacy from previously disclosed data at ASCO 2024. The results showed that in patients with known CLDN18.2 and PD-L1 status, the median progression-free survival (mPFS) reached 14.2 months for those with H/M CLDN18.2 expression, with a confirmed objective response rate of 68%. The vast majority of these patients are PD-L1 CPS<5. Read full news: https://lnkd.in/gXrjhZjP

In a recent interview with PharmaBoardroom, Transcenta's CEO, Dr. Xueming Qian, outlines company’s progress, including its Osemitamab (TST001) global Phase III trial and the continuous manufacturing capability it has developed, and weighs in on varying investor response as well as the Chinese biotech ecosystem.   Read the article to learn more about Transcenta‘s dedication to science. By focusing on scientific innovation and developing differentiated products that meet patient needs, we are paving a clear path forward.   https://lnkd.in/dz3JJkUq   #Healthcare #IndustryInsight #LeadingVoices #Biotech #Osemitamab #TST001

It's great that we are implementing a highly intensified hybrid continuous biomanufacturing process to produce Osemitamab, to improve quality and speed, while significantly reducing cost of goods to make it more affordable.  However, nothing is more exciting and rewarding than seeing the big difference we make for patients!!!

Transcenta announces study results from the Phase I/IIa Cohort-G data for Osemitamab (TST001) plus Nivolumab and CAPOX as the first-line treatment of patients with advanced G/GEJ cancer. The results showed that median progression-free survival (mPFS) reached 12.6 months in patients with H/M CLDN18.2 expression, any PD-L1 CPS, as well as in the 80% of patients with PD-L1 CPS<5. Using the group of patients with very low/no CLDN18.2 expression as surrogate control, the HR for the triple combination is 0.443 (95%CI, 0.205-0.958) in favor of the H/M expressors and in these patients, the confirmed overall response rate was 68%. Read full news: https://lnkd.in/gFCpfmQS #ASCO